Evaluation of specialty drug price trends using data from retrospective pharmacy sales transactions

Journal of Managed Care and Specialty Pharmacy

Volumn 22, Issue 9, 2016, Pages 1010-1017

  Penington, Robert ^a   Stubbings, Jo Ann ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBULATORY CARE; ARTICLE; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; HUMAN; PATIENT CARE; PHARMACY; PRESCRIPTION; RETROSPECTIVE STUDY; THERAPY EFFECT; WHOLESALE ACQUISITION COST; COMMERCIAL PHENOMENA; DRUG MANUFACTURE; ECONOMICS; EVALUATION STUDY; FEMALE; MALE; TRENDS;

BIOLOGICAL PRODUCT;

BIOLOGICAL PRODUCTS; COMMERCE; DRUG COSTS; FEMALE; HUMANS; MALE; ORPHAN DRUG PRODUCTION; PHARMACEUTICAL SERVICES; PHARMACIES; PHARMACY; RETROSPECTIVE STUDIES;

EID: 84990967376     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2016.22.9.1010     Document Type: Article

References (31)

1. Spatz I, Mcgee N. Health Policy Brief: Specialty pharmaceuticals. Health Affairs. November 25, 2013. Available at: http://www.healthaffairs.org/ healthpolicybriefs/brief.php?brief_id=103. Accessed August 10, 2016.
2. Hagerman J, Freed S, Rice G. Specialty pharmacy: a unique and growing industry. American Pharmacists Association. July 1, 2013. Available at: http://www.pharmacist.com/specialty-pharmacy-unique-and-growingindustry. Accessed August 10, 2016.
3. CVS Specialty. Comprehensive specialty pharmacy drug list. July 2016. Available at: https://www.cvsspecialty.com/wps/wcm/connect/d5405d7b-685e-4377-b998-2e4c4daf0b13/SpecialtyDrugs.pdf?MOD=AJPERES&CACHEID= d5405d7b-685e-4377-b998-2e4c4daf0b13. Accessed August 10, 2016.
4. U.S. Food and Drug Administration. Search orphan drug designations and approvals. Available at: http://www.accessdata.fda.gov/scripts/opdlisting/ oopd/. Accessed August 10, 2016.
5. Meekings KN, Williams CS, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today. 2012;17(13-14):660-64.
6. Kesselheim A. Appendix B: Innovation and the Orphan Drug Act, 1983-2009: regulatory and clinical characteristics of approved orphan drugs. In: Institute of Medicine, Committee on Accelerating Rare Diseases Research and Orphan Product Development; Field MJ, Boat TF, eds. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: National Academies Press; 2010. Available at: http://www.ncbi.nlm.nih.gov/ books/NBK56187/. Accessed August 10, 2016.
7. Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J. Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis. 2008;16;3:33. Available at: http://www.ncbi.nlm.nih. gov/pmc/articles/PMC2631478/. Accessed August 10, 2016.
8. Asbury CH. The Orphan Drug Act. The first 7 years. JAMA. 1991;265(7):893-97.
9. Braun MM, Farag-El-Massah S, Xu K, Coté TR. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov. 2010;9(7):519-22.
10. Specialty pharmaceuticals: facts, figures and trends executive summary. Specialty Pharma Journal. 2012. Available at: http://www.specialtypharmajournal. com/medical-news/business-news/3554-specialty-pharmaceuticalsfacts-figures-and-trends-executive-summary. Accessed August 10, 2016.
11. UnitedHealth Center for Health Reform & Modernation. The growth of specialty pharmacy: current trends and future opportunities. April 2014. Available at: http://www.unitedhealthgroup.com/~/media/UHG/PDF/2014/ UNH-The-Growth-Of-Specialty-Pharmacy.ashx. Accessed August 18, 2016.
12. Pharmaceutical Strategies Group. Press release. Pharmaceutical Strategies Group to detail how to better control pharmacy benefit, specialty drug costs at ASHHRA conference. Business Wire. September 18, 2015. Available at: http://www.businesswire.com/news/home/20150918005132/ en/Pharmaceutical-Strategies-Group-Detail-Control-Pharmacy-Benefit. Accessed August 18, 2016.
13. Hartung DM, Bourdette DN, Ahmed SM, Whitham RH. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? Neurology. 2015;84(21):2185-92. Available at: http://www.ncbi.nlm.nih. gov/pmc/articles/PMC4451044/. Accessed August 10, 2016.
14. Lotvin AM, Shrank WH, Singh SC, Falit BP, Brennan TA. Specialty medications: traditional and novel tools can address rising spending on these costly drugs. Health Aff (Millwood). 2014;33(10):1736-44.
15. Academy of Managed Care Pharmacy. AMCP guide to pharmaceutical payment methods (version 3.0). 2013. Available at: http://www.amcp.org/ pharmaceutical-payment-guide/. Accessed August 10, 2016.
16. Gencarelli DM. Average wholesale price for prescription drugs: is there a more appropriate pricing mechanism? NHPF Issue Brief. 2002;(775):1-19. Available at: https://www.nhpf.org/library/issue-briefs/IB775_AWP_6-7-02.pdf. Accessed August 10, 2016.
17. Curtiss FR, Lettrich P, Fairman KA. What is the price benchmark to replace average wholesale price (AWP)? J Manag Care Pharm. 2010;16(7): 492-501. Available at: http://www.jmcp.org/doi/10.18553/jmcp.2010.16.7.492.
18. Historical inflation rates: 1914-2015. U.S. Inflation Calculater. Available at: http://www.usinflationcalculator.com/inflation/historical-inflation-rates/. Accessed August 8, 2015.
19. Pharmacy Practice News. Special report: understanding key differences between biosimilars and small molecule generics. May 2013. Available at: http://www.pharmacypracticenews.com/download/sr1229_wm.pdf. Accessed August 10, 2016.
20. U.S. pharma market will top $377 billion in 2014; up 11-13%. Pharmaceutical Commerce. November 20, 2014. Available at: http://pharmaceuticalcommerce. com/latest_news?articleid=27416. Accessed August 10, 2016.
21. Herper M. Why big pharma won't get its piece of the $1.2 trillion global drug market. Forbes. July 12, 2012. Available at: http://www.forbes.com/ sites/matthewherper/2012/07/12/the-global-drug-market-will-swell-to-1-2-trillion-while-big-pharma-treads-water/#3eef3e9b13fb. Accessed August 10, 2016.
22. Fein AJ. Diplomat shows specialty pharmacy's profits and infusion's promise. Drug Channels. March 24, 2015. Available at: http://www. drugchannels.net/2015/03/diplomat-shows-specialty-pharmacys.html. Accessed August 10, 2016.
23. Kunze AM, Gunderson BW, Gleason PP, Heaton AH, Johnson SV. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs-pharmacy and medical benefit spending from 2004 through 2007. J Manag Care Pharm. 2007;13(9):799-806. Available at: http:// www.jmcp.org/doi/abs/10.18553/jmcp.2007.13.9.799.
24. Tegenu M. Health plan approach to operationalizing a specialty drug management program. J Manag Care Pharm. 2008;14(4 Suppl A):S17-21. Available at: http://www.jmcp.org/doi/pdf/10.18553/jmcp.2008.14.S4-A.17.
25. Navarro RP, Johnson KA. Opportunities and challenges of specialty pharmaceuticals. J Manag Care Pharm. 2013;19(1):70-71. Available at: http:// www.jmcp.org/doi/10.18553/jmcp.2013.19.1.70.
26. Gleason PP, Alexander GC, Starner CI, et al. Health plan utilization and costs of specialty drugs within 4 chronic conditions. J Manag Care Pharm. 2013;19(7):542-48. Available at: http://www.jmcp.org/doi/10.18553/ jmcp.2013.19.7.542.
27. Kaisaeng N, Harpe SE, Carroll NV. Out-of-pocket costs and oral cancer medication discontinuation in the elderly. J Manag Care Spec Pharm. 2014;20(7):669-75. Available at: http://www.jmcp.org/doi/10.18553/ jmcp.2014.20.7.669.
28. Sullivan SD. The promise of specialty pharmaceuticals: Are they worth the price? J Manag Care Pharm. 2008;14(4 Suppl A):S3-6. Available at: http:// www.jmcp.org/doi/abs/10.18553/jmcp.2008.14.S4-A.3.
29. U.S. Food and Drug Administration. FDA news release. FDA approves first biosimilar product Zarxio. March 6, 2015. Available at: http://www. fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm. Accessed August 10, 2016.
30. Kober S. The evolution of specialty pharmacy. Biotechnol Healthc. 2008;5(2):50-51.
31. Tharaldson A. Pipeline update: anticipated specialty drug approvals. Express Scripts: The Lab. September 25, 2014. Available at: http://lab. express-scripts.com/insights/drug-options/pipeline-update-anticipatedspecialty-drug-approvals. Accessed August 10, 2016.